Organogenesis Holdings Inc. (NASDAQ:ORGO) Director Wayne D. Mackie bought 42,726 shares of the firm’s stock in a transaction on Tuesday, November 17th. The stock was acquired at an average price of $3.25 per share, for a total transaction of $138,859.50. Following the transaction, the director now owns 161,290 shares of the company’s stock, valued at $524,192.50. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

NASDAQ:ORGO opened at $5.08 on Friday. The stock’s 50-day moving average is $4.03 and its 200-day moving average is $3.92. The company has a current ratio of 1.78, a quick ratio of 1.35 and a debt-to-equity ratio of 2.95. The stock has a market cap of $547.55 million, a P/E ratio of -13.73 and a beta of 1.33. Organogenesis Holdings Inc. has a 1-year low of $2.47 and a 1-year high of $7.01.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings data on Monday, November 9th. The company reported $0.19 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.27. Organogenesis had a negative return on equity of 101.41% and a negative net margin of 13.58%. As a group, equities analysts forecast that Organogenesis Holdings Inc. will post -0.36 EPS for the current year.

Several institutional investors have recently bought and sold shares of the stock. State Street Corp lifted its stake in shares of Organogenesis by 33.2% in the third quarter. State Street Corp now owns 259,014 shares of the company’s stock worth $995,000 after acquiring an additional 64,493 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Organogenesis by 10.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 165,676 shares of the company’s stock worth $637,000 after acquiring an additional 16,196 shares during the period. Bank of Montreal Can lifted its stake in shares of Organogenesis by 5.5% in the second quarter. Bank of Montreal Can now owns 130,974 shares of the company’s stock worth $435,000 after acquiring an additional 6,868 shares during the period. Squarepoint Ops LLC lifted its stake in shares of Organogenesis by 227.4% in the third quarter. Squarepoint Ops LLC now owns 67,502 shares of the company’s stock worth $259,000 after acquiring an additional 46,883 shares during the period. Finally, Bank of New York Mellon Corp lifted its stake in Organogenesis by 95.0% in the second quarter. Bank of New York Mellon Corp now owns 55,338 shares of the company’s stock valued at $213,000 after buying an additional 26,963 shares during the period. 4.15% of the stock is currently owned by institutional investors.

A number of research firms have issued reports on ORGO. Zacks Investment Research upgraded Organogenesis from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research report on Wednesday, October 14th. Oppenheimer restated a “buy” rating and set a $9.00 price target on shares of Organogenesis in a report on Monday, September 21st. SVB Leerink boosted their price target on Organogenesis from $9.00 to $10.00 and gave the stock an “outperform” rating in a report on Wednesday. BidaskClub cut Organogenesis from a “hold” rating to a “sell” rating in a report on Friday, September 25th. Finally, Credit Suisse Group boosted their price target on Organogenesis from $7.00 to $8.00 and gave the stock an “outperform” rating in a report on Tuesday, November 10th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $8.30.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.

Read More: Pattern Day Trader – What is the PDT Rule?

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.